| Revenue Growth | Organic revenue up 2.6%; excluding Clinical Genomics, growth was 5%. |
|---|---|
| Mgmt Confidence | Conservative guidance based on first-half data; management won't claim victory yet. |
| Demand Visibility | IPD issues are manufacturing-related, not demand-related; backlogs mentioned at $103.9 million. |
| Order Book | Backlog of $103.9 million mentioned; timing of consumer orders impacted genomics. |
| Margin Trends | Gross profit 67.4%; adjusted EBITDA expected to grow faster than revenues. |
| Op. Leverage | Savings plan to reduce annualized operating costs by $9.3 million. |
| Segment Growth | Sterilization mid-teens; Calibration low single digits; Biopharmaceutical development weak. |
| Capex & Debt | Repaid $20.1 million debt; net leverage 1.75x; $40 million share buyback. |
| Regulatory | Export control issues impacted August orders in biopharmaceutical development. |
| Commentary | Managing Clinical Genomics for profitability, not scale; every business competes for capital. |
| New Launches | New platform B.P.E. on track to launch in fiscal 2028. |
Growth
Organic revenue grew 2.6%; Sterilization/Disinfection grew mid-teens; Calibration grew low single digits.
Outlook
FY2024 revenue guidance of $250 million to $255 million; adjusted EBITDA growth of 5% to 8%.
Risks
Biopharmaceutical development had a weak quarter; manufacturing delays in IPD are real and not yet fixed.
The company's earnings call, NASDAQ: MLAB, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Mesa Laboratories Inc: key numbers
- Share price
- $134.09Close, Nov 16
- Market cap
- $754M
- Shares outstanding
- 5.62MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Industrial Instruments For Measurement, Display, and ControlSIC 3823
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mesa Laboratories Inc
All →Mesa Laboratories Financial Results
Mesa Laboratories reported second quarter fiscal 2027 results with revenues increasing 2.6% to $62.3 million and net income rising 75.3% to $4.3 million. The company issued full-year fiscal 2027 guidance for the first time, forecasting revenues between $250 million and $255 million. Performance was driven by record revenues in the Sterilization and Disinfection Control division, partially offset by export-control delays in the Biopharmaceutical Development segment.
- Term
- Q2 2027
“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”
Dr. Siddhartha Kadia, President and CEO
“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”
John Sakys, Chief Financial Officer
Mesa Laboratories Q2 2026 Results: Net Income $4.34M, Up 75.3% YoY
Mesa Laboratories reported Q2 2027 revenues of $31.6 million, a slight increase from $30.1 million in the prior year period. Net income for the quarter was $0.97 million ($0.16 per share), down from $1.63 million ($0.16 per share) in the same quarter last year, reflecting shifts in segment performance across sterilization, biopharmaceutical, and clinical genomics units.
- Key figure
- Net income $4.34M · +75.3% YoY
Mesa Laboratories Business Update
Mesa Laboratories approved a restructuring program to reduce annualized operating costs by approximately $9.3 million, primarily by focusing its Clinical Genomics division on pharmacogenomics and oncology. The plan involves eliminating 40 positions (6% of the workforce) and exiting a facility in Hamburg, Germany, with an estimated $2.6 million to $3.4 million in pre-tax charges.